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Abstract: Domperidone and Itopride are pro-kinetic agents, regulating the 
gastric motility and are commonly prescribed as anti emetic drugs. In the 
present study a simple, rapid and sensitive RP-HPLC/UV method was 
developed for simultaneous determination of Domperidone and Itopride in 
pharmaceutical samples and human plasma, using Tenofavir as internal 
standard. Experimental conditions were optimized and method was validated 
according to the standard guidelines. Combination of water (pH 3.0) and 
acetonitrile (65:35 v/v) was used as mobile phase, pumped at the flow 
rate of 1.5ml/min. Detector wavelength was set at 210nm and column oven 
temperature was 40oC. Unlike conventional liquid-liquid extraction, 
simple precipitation technique was applied for drug extraction from human 
plasma using acetonitrile for deprotienation.  
The method showed adequate separation of both the analytes and best 
resolution was achieved using Hypersil BDS C8 column (150mm x 4.6mm, 
5µm). The method was quite linear in the range of 20 - 600ng/ml. Recovery 
of the method was 92.31% and 89.82% for Domperidone and Itopride, 
respectively. Retention time of both the analytes and internal standard 
was below 15min. The lower limit of detection (LLOD) and lower limit of 
quantification (LLOQ) for Domperidone were 5 and 10ng/ml while for 
Itopride was 12 and 15ng/ml, respectively.  
The developed method was successfully applied for in-vivo analysis of 
fast dispersible tablets of Domperidone in healthy human volunteer. The 
proposed method was a part of formulation development study and was 
efficiently applied for determination of the two drugs in various 
pharmaceutical products and human plasma. 
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1. Introduction 1 
Domperidone (6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl) propyl] piperidin-4-yl]-1H 2 
benzimidazol-2-one) is structurally related to butyrophenones having molecular formula of 3 
C22H24ClN5O2 and molecular weight of 425.91g/mol [1, 2]. It is a class-2 drug having pH 4 
dependent solubility. Experimental water solubility of Domperidone is 0.986mg/L and its Pka 5 
value is 7.9 [3]. Domperidone is commonly prescribed as anti emetic with daily recommended 6 
dose of 10 – 40 mg in divided doses.  7 
Itopride (N-[[4-(2-dimethylaminoethoxy) phenyl] methyl]-3, 4-dimethoxy-benzamide HCl) is a 8 
prokinetic agent. Chemically it is a substituted benzamide with molecular formula of 9 
C20H26N2O4.HCl and molecular weight of 394.89g/mol having pKa value of 8.72 [4, 5]. 10 
Physically it is a crystalline solid and freely water soluble. Recommended dose of Iopride for 11 
adult patients is 150mg/day in divided doses [6]. Structural formulae of Domperidone and 12 
Itopride are presented in Fig-1. 13 
Both Domperidone and Itopride are prescribed for treatment of gastric esophageal reflux 14 
disorders (GERD) and are commonly used anti emetic [7]. Domperidone and Itopride regulate 15 
the gastric motility [8, 9] by;  16 
 Antagonizing inhibitory effect of dopamine at D2 receptors  17 
 Increasing stimulatory effect of acetylcholine by blocking its metabolizing enzyme 18 
acetylcholine esterase 19 
To date several reversed phase high performance liquid chromatography (RP-HPLC) methods 20 
have been reported for analysis of Domperidone and Itopride. Most of the methods are 21 
applicable only for analysis of the drugs in various pharmaceutical dosage forms [10 – 19]. Due 22 
to lack of sensitivity, these methods cannot be applied for analysis of the drugs in biological 23 
samples. Few methods exhibited better sensitivity but involved derivatization technique and post 24 
column photochemical reactions [12]. In these methods drug was extracted from biological 25 
matrix using tedious and costly technique of solid phase extraction (SPE). In most of the reported 26 
methods, mobile phase composition is very complex, using buffer solutions as aqueous phase 27 
[13, 14, 16].   28 
It was required to develop a rapid, sensitive and simple method involving no derivatization or 29 
other advanced technique. The aim of the presented work was to develop a sensitive, rapid and 30 
simple RP-HPLC/UV method for simultaneous determination of Domperidone and Itopride in 31 
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pharmaceutical and biological samples (human plasma). The suggested method is economical, 1 
involves simple extraction procedure, requires lesser sample volume and possesses a shorter 2 
chromatographic analysis run time as compared to other reported methods. The developed 3 
method was successfully applied for in-vivo evaluation of fast dispersible tablets of 4 
Domperidone in human volunteers.  5 
 6 
2. Experimental 7 
2.1 Chemicals and reagents 8 
Domperidone (purity 99.9%) was provided by Medicraft Pharmaceuticals, Peshawar, Pakistan, 9 
Itopride (purity 99.75%) and Tenofovir were gifted by Ferozsons Laboratories Ltd. Nowshera, 10 
Pakistan. HPLC grade acetonitrile (purity 99.9%), methanol (purity 99.9%) and analytical grade 11 
ortho-phosphoric acid (OPA; purity 85%) were purchased from Sigma–Aldrich (Oslo, Norway). 12 
Ultra pure HPLC grade water was prepared by Milli-Q® system (Millipore, Milford, MA, USA).  13 
2.2. Instrumentation  14 
Chromatographic analysis was performed using HPLC system equipped with an auto sampler, 15 
vacuum degasser, peltier column oven, pump, and UV–visible detector (Perkin Elmer Series 200 16 
system, Norwalk, USA). The chromatographic data was analyzed on Perkin Elmer Total-chrom 17 
workstation software (version 6.3.1, Bridgeport, USA) linked with the LC-system through 18 
network chromatography interface (NCI) 900. Separation of the analytes was carried out using 19 
Hypersil BDS C8 column (150mm x 4.6mm, 5µm) protected by a Perkin Elmer pre-column 20 
guard cartridge C18 (30mm × 4.6mm, 10µm; Norwalk, USA). 21 
2.3 Optimization of chromatographic conditions 22 
Different mobile phases, consisting of acetonitrile, acidified water (pH adjusted to 3.0 with OPA; 23 
35:65, v/v), methanol, acetonitrile and acidified water (pH adjusted to 3.0 with OPA; 25:25:50 24 
v/v) and methanol, acidified water (25:75, v/v), pumped with different flow rates in the range of 25 
0.5 – 2.0 ml/min in an isocratic mode were evaluated. Chromatographic analyses were performed 26 
at different column oven temperatures in the range of 25 – 50 oC. The injection volume was 27 
studied in the range of 10 – 50 µl.  28 
2.4 Preparation of standard solutions  29 
Stock solutions of Domperidone and Itopride and Tenofovir (concentration = 1.0mg/ml) were 30 
prepared in methanol and water, separately, on the basis of their respective solubility and stored 31 
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at –4oC. Stock solutions were diluted with the mobile phase (acetonitrile: water, 35:65, v/v) to 1 
obtain various dilutions in the range of 10 – 600ng/ml (i.e., 10, 50, 100, 200, 400, 500 and 2 
600ng/ml).  3 
2.5 Sample preparation  4 
Stock solution of both analytes and internal standard were prepared separately in water and 5 
organic solvent (methanol), on the basis of their respective solubility. Stock solutions of 6 
Domperidone and internal standard (Tenofovir) were prepared in methanol while purified water 7 
was used for preparation of Itopride solution. Concentration of the stock solutions of all the 8 
compounds was 1mg/ml. Working solutions (10ml) of both analytes were prepared by dilution of 9 
stock solution with mobile phase on daily basis.  10 
Blood samples (about 3ml) collected from healthy human volunteers in the ethylene diamine 11 
tetraacetic acid (EDTA) tubes were centrifuged at 4000 × g for 10min at 4
o
C to separate plasma. 12 
The isolated plasma was deproteinated with acetonitrile. Aliquot of plasma (200µl) was taken in 13 
Eppendorf tube (capacity = 1ml), acetonitrile (600µl) was added and vertexed for 2min. Sample 14 
was centrifuged at 4000 x g for 10min and supernatant was collected using posture pipette. The 15 
separated plasma was stored at –20oC till further use.  16 
On the day of analysis, plasma samples were thawed at room temperature and spiked with 17 
appropriate concentrations of working solutions to obtain calibration standards {in the range 10 – 18 
600ng/ml (Domperidone) and 15 – 600ng/ml (Itopride)}. The calibration curves covered the 19 
maximum therapeutic concentrations achieved by both the drug in-vivo. The amount of stock 20 
solution in all spiked samples was kept below 2.0% of the total sample volume to minimize any 21 
systematic errors between real samples and standards.  22 
2.6 Sample collection and extraction 23 
Plasma samples (200µl) were spiked with known amount of Domperidone, and Itopride, internal 24 
standard solution (10µl) was added and mixed for 10s. Unlike traditional liquid-liquid extraction, 25 
simple precipitation technique was applied for drug extraction from biological sample. That is 26 
the sample was deproteinated with acetonitrile and diluted with mobile phase. Schematic 27 
presentation of extraction procedure is shown in Fig-2.  28 
 29 
 30 
 31 
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2.7 Validation of the developed method 1 
The suggested method was validated according to standard guidelines [20 – 22] with emphasis 2 
on linearity, precision, specificity/selectivity, accuracy, sensitivity (lower limit of detection and 3 
lower limit of quantification), sample stability, and robustness. 4 
2.7.1 Linearity 5 
Linearity of the method was evaluated from the calibration curves constructed at seven different 6 
concentration points of both the analytes in spiked plasma and mobile phase (standard solutions). 7 
The concentration range for calibration curve was 10 – 600ng/ml. The ratio of the peak area of 8 
each analyte to the area of internal standard was plotted against their corresponding 9 
concentration [23, 24] and slope (a), intercept (b) correlation coefficient (r) and covariance 10 
(%RSD) were determined from the regression analysis using the least squares method. 11 
2.7.2 Precision 12 
Precision of the method was determined in terms of injection repeatability and analysis 13 
repeatability of spiked plasma samples. In order to determine injection repeatability, plasma 14 
samples spiked with 250ng/ml each of Domperidone and Itopride were injected (n = 5) into 15 
HPLC. Peak area and retention time of both the drugs were determined and results were 16 
expressed as mean and covariance (mean; %RSD). Analysis repeatability was verified by 17 
determining the recovered amount from plasma samples spiked with known concentration of 18 
both drugs (Domperidone and Itopride). Results were presented as mean; %RSD (n = 5).  19 
To determine intermediate precision (intra-day and inter day reproducibility), plasma samples 20 
spiked with different concentrations of Domperidone and Itopride were analyzed three times a 21 
day (at 8 hours interval) on day-1 (intraday). Inter day study was carried out by analyzing the 22 
same sample (spiked samples used in intraday study) on daily basis for next three days. The 23 
results were presented as mean ± standard deviation; covariance (n = 5).  24 
2.7.3 Selectivity/specificity  25 
The specificity of the method was evaluated by verifying the complete separation of the peaks of 26 
both the analytes and internal standard in standard solutions (solutions of both analytes prepared 27 
in mobile phase) and spiked plasma samples [23].  28 
2.7.4 Accuracy 29 
Percent recovery was used for determination of accuracy of the proposed method [24]. Percent 30 
recovery was calculated by spiking the biological sample at three appropriately nominated 31 
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concentrations (100, 250 and 500ng/ml) of both the analytes. Concentration of internal standard 1 
(Tenofovir) was kept constant and extraction was made using mobile phase. Sample (20µl) was 2 
injected into the HPLC system in triplicate (n = 3) and percent recovery was calculated using 3 
following equation; 4 
 5 
                              --------------- Eq-1 6 
Where  7 
A = Peak area response ratios of the analytes with reference to IS in the plasma samples  8 
B = Peak area response ratios of the analytes with reference to IS mobile phase  9 
 10 
Amount recovered from each sample was calculated using the following equation;  11 
 12 
                            ----------------- Eq-2 13 
Where  14 
X and Y = Peak areas of the analyte in plasma samples and 1:1 mixture, respectively  15 
A and B = Peak areas of the internal standard in 1:1 mixture and plasma samples,  16 
Cs = Concentration of analyte in the 1:1 mixture  17 
FD = Dilution factor  18 
 19 
Standard deviation (SD) and covariance (%RSD) were calculated for each sample 20 
2.7.5 Sensitivity 21 
Sensitivity of the method was evaluated on the basis of determination of the lower limit of 22 
detection (LLOD) and lower limit of quantification (LLOQ) for both the analytes. Signal to noise 23 
ratio (S/N) was determined for each analyte using HPLC software. Lower limit of detection was 24 
the concentration at which signal to noise ratio was 3 (S/N ≈ 3) and lower limit of quantification 25 
(LLOQ) was the concentration at which S/N ratio was 10 (S/N ≈ 10).    26 
 27 
 28 
 29 
2.7.6 Sample stability 30 
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Stability of both the analytes was evaluated by keeping samples at various temperatures. Samples 1 
of both the analytes were stored at room temperature and –20 oC for one week and analyzed. 2 
Percent stability and percent loss were calculated using the following equations [24, 25]; 3 
                       ------------------------- Eq-3 4 
                           ------------------- Eq-4 5 
Where  6 
St = Stability of analyte at time t  7 
S0 = Stability at initial time (stability of fresh solution) 8 
 9 
2.7.7 Robustness 10 
Robustness of the method was estimated by changing various experimental conditions and 11 
evaluating their effect on peak area, peak height and retention time of both the analytes. Small 12 
deliberate changes were made in different chromatographic condition like column oven 13 
temperature (±5
o
C), mobile phase composition, mobile phase flow rate (± 0.2 ml/min), detector 14 
wave length (± 2nm) and detector voltage (± 50 mV).  15 
2.8 Statistical interpretation and correlation of data 16 
Various statistical tools such as mean (X), standard deviation (SD) and relative standard 17 
deviation (%RSD) were calculated using MS Excel and applied for quantification of both the 18 
analytes.  19 
2.9 Application of the method in pharmacokinetic evaluation of fast dispersible tablets of 20 
Domperidone  21 
The method was transferred to the Biopharmaceutical Laboratory of the Department of 22 
Pharmacy, University of Peshawar, Pakistan. The method transfer was controlled by a procedure 23 
including development of a transfer plane, definition of transfer tests and acceptance criteria 24 
(sample analysis: sample time and replication, validation experiments), training of laboratory 25 
staff and full method validation. The method parameters were identical with regard to mobile 26 
phase composition, HPLC column, detector wavelength and extraction procedure. The HPLC 27 
system was different and minor modifications to the laboratory procedures had to be made in 28 
order to adapt it to the local conditions. The clinical application of the method was assessed by 29 
measuring Domperidone in plasma samples of healthy human volunteers (Pharmacy Graduates 30 
in the Department of Pharmacy, University of Peshawar). The study was conducted according to 31 
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the guidelines of “World Medical Associations, Declaration of Helsinki-ethical principles for 1 
medical research involving human subjects” and was approved by the institutional “Committee 2 
for Research Ethics”, Department of Pharmacy, University of Peshawar, under license number 3 
“UOP/PHARM-EC/387”. 4 
Fast dispersible tablet of Domperidone was dispersed in a glass of water (200ml) and taken by 5 
each volunteer. Blood samples (3ml) were obtained at specified time intervals (0, 5, 15, 30, 60, 6 
120, 180, 240, 300 and 360min) following tablet administration. Blood samples were collected in 7 
EDTA tubes and centrifuged at 4000 x g for 10min at 4 
o
C to separate the plasma.  8 
Deproeination of plasma samples was carried out using acetonitrile. An aliquot of plasma 9 
(200µl), together with internal standard was taken in eppendorf tube, acetonitrile (3 times 10 
volume of plasma sample) was added to it, vertexed for 2min and centrifuged at 4000 x g for 11 
5min. Supernatant was isolated in a separate eppendorf tube (1ml capacity), volume was made 12 
up with mobile phase and vertexed for 1min. The plasma samples, isolated in separate eppendorf 13 
tubes, were stored at –20 oC till further analysis. On the day of analysis, the frozen samples were 14 
thawed at room temperature. The samples were analyzed in triplicate to ensure satisfactory 15 
method performance in accordance with the standard guidelines. 16 
The plasma concentration of Domperidone in human plasma samples was quantified at various 17 
time intervals following oral administration of fast dispersible tablets. The data was fitted in the 18 
compartmental models to calculate various pharmacokinetic parameters such as tmax, Cmax, Half 19 
life (t ½) and area under cure (AUC). The pharmacokinetic data was assessed using Microsoft 20 
Excel 2007 and PK-Summit®, a pharmacokinetics software. 21 
3. Results and Discussion 22 
Domperidone and Itopride were analyzed for first time simultaneously using Tenofavir as 23 
internal standard. Various experimental conditions were optimized and method was validated 24 
according to the ICH guidelines [22]. The proposed method was a rapid one and all the analytes 25 
were separated within 15min. Of the various analytical conditions studied, best results were 26 
achieved with the Hypersil BDS C8 Column (150mm x 4.6mm, 5µm) column, flushed with 27 
combination of acetonitrile and acidified water (35:65, v/v) as the mobile phase, pumped at a 28 
flow rate of 1.5ml/min at 40 
o
C.  29 
 30 
 31 
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3.1 Sample preparation 1 
Methanol, acetonitrile and 1:1 mixture of methanol and acetonitrile were evaluated for protein 2 
precipitation; however better protein precipitation was achieved with acetonitrile. Volume of 3 
acetonitrile at least 3 times the volume of plasma was used for protein precipetation.  4 
3.2 Optimization of analytical conditions and experimental parameters 5 
Hypersil BDS C8 Column (150 x 4.6mm, 5µm) column was used for separation of Domperidone 6 
and Itopride. Other columns like Discovery HS C18 column (150mm × 4.6mm, 5µm), Symmetry 7 
C8 column (150mm × 3.9mm, 5µm) and Symmetry C8 (250mm × 4.6mm, 5µm) were also tried. 8 
With these peaks overlapping and broadening were observed for both analytes. Hypersil BDS C8 9 
(150mm x 4.6mm, 5µm) column was selected as the best on the basis of excellent peak 10 
parameters (retention, separation, tailing, asymmetry, and resolution) and shorter run time. 11 
Different combinations of organic solvents (methanol and acetonitrile) and water were used as 12 
mobile phase. Water used in preparation of mobile phase was acidified (pH adjusted to 3) with 13 
ortho phosphoric acid (85%) avoiding use of buffer solution. Different isocratic solvent systems, 14 
consisting of acetonitrile–acidified water (25:75, 35:65 and 50:50, v/v), methanol–acidified 15 
water (25:75 and 50: 50, v/v) and methanol–acetonitrile-acidified water (25:25: 50, v/v) were 16 
assessed as the mobile phases. In comparison to methanol, acetonitrile resulted in better peak 17 
area and peak shape so acetonitrile was included as organic solvent in mobile phase. 18 
It was noticed that increase in ratio of acetonitrile in mobile phase decreased retention time of all 19 
the compounds resulting in shorter analysis time but peak area and peak height were significantly 20 
affected. Domperidone is water insoluble compound and by increasing ratio of acetonitrile in 21 
mobile phase resulted in increased sensitivity of the method for Domperidone. Similarly area of 22 
Itopride reduced with increasing quantity of acetonitrile in mobile phase. Combination of 23 
acetonitrile and acidified water (35: 65, v/v) resulted in the best results in terms of peak shape, 24 
area, retention time and resolution and was selected as mobile phase for further analysis. 25 
Mobile phase of different pH was prepared by changing pH of water in the range of 2 – 5 with 26 
O-phosphoric acid. Sensitivity and retention time of all the compounds were significantly 27 
affected by pH of the mobile phase. At higher pH sensitivity of the method was reduced and 28 
retention time was increased for all the compounds. Effect of changes in pH was more prominent 29 
with Domperidone as its retention time was increased up to 20min with very low sensitivity 30 
(Fig-3). At lower pH retention time decreased but separation between Domperidone and Itopride 31 
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was also reduced significantly. Best peak shape with better resolution and sensitivity were 1 
obtained at pH 3 and was selected as optimum pH of mobile phase for further analysis. 2 
Retention time, peak shape and peak area were significantly affected by flow rate of the mobile 3 
phase. Best results were obtained at flow rate of 1.5ml/min and selected as optimum flow rate for 4 
further analysis. 5 
Column oven temperature was studied in the range of 25 – 50 oC and best results were obtained 6 
at 40 
o
C. At higher column oven temperature, sensitivity of the method was increased with 7 
improved peak height. Better peak shape and resolution were obtained at 40 
o
C and selected as 8 
column oven temperature for simultaneous determination of the two drugs. 9 
Internal standard was selected on the basis of its specificity, sensitivity, recovery and 10 
compatibility with Domperidone and Itopride. Various compounds like Ciprofloxacin, Naproxin 11 
Sodium, Tenofovir and Atenolol were tried as internal standard. Among them Tenofovir 12 
exhibited better recovery and peak separation and was used as internal standard. 13 
3.3 Method validation 14 
The proposed method of analysis was validated according to standard guidelines in terms of 15 
selectivity, sensitivity, recovery, precision and robustness.  16 
3.3.1 Specificity and selectivity 17 
The proposed method of analysis was highly selective and specific as peaks of both analytes and 18 
internal standard were well resolved. Separation of peaks was confirmed by using blank plasma, 19 
plasma spiked with both analytes and internal standard. The method is well suitable for analysis 20 
of Domperidone and Itopride in pharmaceutical solutions as well as biological samples.  21 
3.3.2 Linearity 22 
Linearity of the method was determined from calibration curve of the standard mixtures and 23 
spiked plasma samples. Calibration curves were constructed at seven concentration levels in the 24 
range of 10 – 600ng/ml for Domperidone and 15 – 600ng/ml for Itopride, separately for standard 25 
mixture and spiked plasma samples. Regression analysis of calibration curves of both drugs 26 
showed that the method is quite linear within the said concentration range. Regression equation 27 
and correlation coefficient values of calibration curves of both the drugs are presented in Table-28 
1. 29 
 30 
 31 
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3.3.3 Accuracy of the method (percent recovery) 1 
Percent recovery from plasma was used for determination of accuracy of the proposed method. 2 
Percent recovery was determined at three concentration levels (100ng/ml, 250ng/ml and 3 
500ng/ml) of both drugs and was found above 91% and 89% for Domperidone and Itopride, 4 
respectively (Table-2). 5 
3.3.4 Precision of the method 6 
Precision of the method was evaluated on the basis of repeatability and intermediate precision. 7 
Intermediate precision was determined in terms of intra and inter day reproducibility. Results of 8 
analysis repeatability, inter day precision and intraday precision are presented in Table-2. There 9 
is complete harmony among repeated injections, repeated analysis, inter day and intraday study.  10 
3.3.5 Stability of Solutions 11 
Stability study was conducted at room temperature (18 – 23 oC) and freezer temperature (-20 oC) 12 
for one week. Both Domperidone and Itopride were stable during the freeze/thaw cycles and for 13 
at least 24hr in each step of the analysis. All the samples were stable at –20 oC for the specified 14 
period. At room temperature Domperidone and internal standard (Tenofavir) remained stable 15 
while Itopride degraded to a significant level. The percent degradation of drugs in both spiked 16 
plasma samples and standard solutions stored at room temperature was higher as compared to the 17 
samples stored at –20 oC. It revealed that all the samples containing Itopride should be stored at –18 
20 
o
C to avoid stability issue.  19 
3.3.6 Sensitivity (Limit of Detection and Lower Limit of Quantification) 20 
Lower limit of detection (LLOD) and lower limit of quantification (LLOQ) of the two drugs are 21 
quite low as presented in Table-1. Values of LLOD and LLOQ proved that the proposed method 22 
was more sensitive than the previously reported method for the drugs. Respective 23 
chromatograms of LLOD and LLOQ of both drugs are given in Fig-4. 24 
3.3.7 Robustness 25 
Minor deliberate changes in analytical parameters did not significantly affect retention times, 26 
percent recovery and peak area of both the drugs. Thus, the method was robust for minor 27 
changes in column oven temperature, i.e., 40 ± 2 
o
C, flow rate, i.e., 1.5 ± 0.2ml/min and pH of 28 
the mobile phase (±0.1 units).  29 
 30 
 31 
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4. Applicability of the method 1 
This method was a part of an extensive formulation development process involving in-vitro and 2 
in-vivo characterization of novel formulations of fast dispersible tablet of Domperidone and 3 
Itopride. The developed method was successfully applied for in-vitro evaluation (drug excipients 4 
compatibility study, determination of drug content and dissolution rate of compressed tablets; 5 
data not shown) and determination of pharmacokinetics of Domperidone in healthy human 6 
volunteers, following oral administration of fast dispersible tablets. The pharmacokinetics study 7 
of fast dispersible tablets of Domperidone (10mg) was carried out in healthy human volunteers 8 
(age range = 24 – 29 years). The study was approved by the “Committee for Research Ethics” of 9 
Department of Pharmacy, University of Peshawar and written consent form was signed by each 10 
volunteer. Drug content of each sample was determined and pharmacokinetic parameters were 11 
calculated using pharmacokinetics software PK Summit.  12 
Applicability of the method is illustrated in Fig-5 showing mean plasma concentration versus 13 
time curve for Domperidone. Various pharmacokinetics parameters determined in healthy human 14 
volunteers (n = 6) are summarized in Table-3. 15 
 16 
5. Conclusion 17 
Using isocratic RP-HPLC with UV detection mode, a simple, rapid and reproducible method for 18 
simultaneous determination of Domperidone and Itopride in human plasma was developed, 19 
optimized and validated. Various experimental parameters such as stationary phase, mobile 20 
phase composition, flow rate, pH of the mobile phase, column oven temperature and internal 21 
standard were optimized. The proposed method was also validated on the basis of linearity, 22 
accuracy, precision, specificity, stability and robustness.  23 
The suggested method offered the advantages of most simple extraction procedure, a short run 24 
time and a small sample volume for analysis. The method is robust, precise and easy to 25 
automate. Baseline separation of Domperidone, Itopride and internal standard was achieved 26 
quickly with no peak interference from endogenous compounds in biological samples. This 27 
method could be efficiently applied for the analysis of Domperidone and Itopride in 28 
pharmaceuticals and biological sample.  29 
 30 
 31 
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Table-1: Calibration range, linearity and sensitivity of the method 
Parameters 
Analytes 
Domperidone Itopride HCl 
Calibration range (ng/ml) 10 – 600 15 – 600 
Linearity 
  Standard mixture 
  Regression equation y = 0.013x +0.017 y = 0.007x +0.006 
Correlation co efficient 0.998 0.999 
Spiked plasma samples 
  Regression equation y = 0.011x + 0.021 y = 0.005x +0.001 
Correlation co efficient 0.997 0.996 
Sensitivity 
  Limit of detection (LOD) 5ng/ml 12ng/ml 
Lower limit of quantification (LLOQ) 10ng/ml 15ng/ml 
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Table-2: Recovery and precision of the method 
Parameter 
Analytes 
Domperidone Itopride HCl 
Recovery 
  
Spiked conc. (100ng/ml) 
a
(91.26); 0.464 
a
(89.82); 0.87 
Spiked conc. (250ng/ml) 
a
(91.10); 0.958 
a
(89.38) ; 1.22 
Spiked conc. (500ng/ml) (n = 5) 
a
(92.31); 0.502 
a
(89.78); 1.98 
Precision 
  
Injection repeatability 
  
Spiked conc. (250ng/ml) 
b
32670; 1.28 
b
24514; 1.097 
Spiked conc. (250ng/ml) (n = 5) 
c
11.39; 1.15 
c
8.37; 0.764 
Analysis repeatability 
  
Spiked conc. (500ng/ml) (n = 5) 
d
0.421; 3.8 
d
0.40; 2.125 
Intermediate precision 
  
Intraday reproducibility 
  
Spiked conc. (100ng/ml) 
d
91.18; 1.54 
d
83.95; 3.74 
Spiked conc. (250ng/ml) 
d
207.50; 2.71 
d
199.12; 3.02 
Spiked conc. (500ng/ml) (n = 5) 
d
418.61; 3.19 
d
399.83; 2.76 
Inter day reproducibility 
  
Spiked conc. (100ng/ml) 
d
89.54; 4.13 
d
85.26; 4.58 
Spiked conc. (250ng/ml) 
d
209.26; 4.16 
d
189.58; 3.97 
Spiked conc. (500ng/ml) (n = 5) 
d
411.59; 1.67 
d
395.30; 4.76 
Results are presented as (mean); %RSD 
a: percent recovery; b: peak area; c: retention time; d: quantity recovered 
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Table-3: Various pharmacokinetic parameters in healthy human volunteers following oral 
administration of fast dispersible tablets of Domperidone (10mg) 
Parameter (Unit) Results 
C max (ng/ml) 24 ± 6.01 
T max (min) 30 ± 5.37 
AUC (ng.hr/ml) 168.7 ± 19.33 
t1/2 (hr) 6.1 ± 1.73  
Results are presented as mean ± S.D. (n = 6) 
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Figure-1: Chemical structures of; A) Domperidone, B) Itopride  
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Figure-2: Extraction procedure of Domperidone and Itopride from human plasma 
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Figure-3: Effect of pH of mobile phase on various peak characteristics,  
Where 1) Internal Standard; 2) Itopride; 3) Domperidone 
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Figure-4: Chromatogram presenting lower limit of detection and lower limit of quantification of 
Domperidone and Itopride  
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Figure-5: Plasma drug concentrations versus time curve for Domperidone given as fast 
dispersible tablets (10mg) single oral dose in healthy human volunteers (mean ± SD, n = 6) 
